bryostatin 1
Trials 39
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 49 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bryostatin-1 | “BACKGROUND: We sought to determine the response rate and toxicity profile of sequential paclitaxel and bryostatin-1, a novel, selective inhibitor of protein kinase C, in...” PMID 18270704 ↗ Feb 200851“Bryostatin-1 is a macrocyclic lactone that has been shown to regulate protein kinase C (PKC) activity and thereby potentially inhibit tumor invasion, angiogenesis, cell...” PMID 15047228 ↗ Apr 2004 “BACKGROUND: Bryostatin-1 is a macrocyclic lactone, which exhibits pleiotropic biological effects via protein kinase C and has shown preclinical synergy with paclitaxel for...” PMID 12581572 ↗ Feb 2003 “A Phase lb Trial of the Combination of Bryostatin-1 and Low Dose Interleukin-2: Evaluation of the Functional and Molecular Status of Human Monocytes as Antigen Presenting Cells” NCT00003993 ↗ “An Open-Label, Non-Randomized Phase I Study of the Protein Kinase C Inhibitor Bryostatin-1 Administered in Combination With Paclitaxel in Patients With Advanced Solid Tumors” NCT00003242 ↗ “The protein kinase C (PKC) agonist bryostatin-1 has shown significant ex-vivo potency to revert HIV-1 latency, compared with other latency reversing agents (LRA).” PMID 26891037 ↗ Jun 2016 “Preclinical data suggested that bryostatin-1 (bryo) could potentiate the cytotoxicity of cisplatin when given prior to this drug.” PMID 19221754 ↗ Feb 2009 “The main purpose of this study is find out how safe a single dose of bryostatin 1 is in patients with Alzheimer's Disease (AD).” NCT00606164 ↗ “A Phase II Trial of Bryostatin-1 In Patients With Metastatic or Recurrent Squamos Cell Carcinoma of the Head and Neck” NCT00003443 ↗ “Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma.” PMID 19738452 ↗ Apr 2010 “A Phase II Trial of Bryostatin-1 for the Treatment of Stage IV Breast Cancer” NCT00003205 ↗ |
| Known as | BRYO | “Preclinical data suggested that bryostatin-1 (bryo) could potentiate the cytotoxicity of cisplatin when given prior to this drug.” PMID 19221754 ↗ Feb 20092“Single-Agent Chemotherapy/Differentiation Therapy. Bryostatin 1, BRYO, NSC-339555.” NCT00002725 ↗ “Bryostatin 1 (BRYO; NSC 339555)” NCT00006022 ↗ |
| Known as | bryostatin | “The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.” NCT02431468 ↗2“Eligible participants will be treated with bryostatin over a 26-week period.” NCT06190912 ↗ “bryostatin 1 (hereafter referred to as bryostatin)” NCT04538066 ↗ |
| Known as | NSC 339555 | “A Phase II Study of Bryostatin-1 (NSC 339555) Plus Paclitaxel in Patients With Metastatic or Unresectable Locally Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction” NCT00006081 ↗4“Phase I Study of Bryostatin 1 (NSC 339555) and Fludarabine in Patients With Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin's Lymphoma” NCT00005580 ↗ “Phase I Study of Bryostatin 1 (NSC 339555) and High-Dose 1-Beta-D-Arabinofuranosylcytosine (HiDAC) in Patients With Refractory Leukemia” NCT00003079 ↗ “Single-Agent Chemotherapy/Differentiation Therapy. Bryostatin 1, BRYO, NSC-339555.” NCT00002725 ↗ “Bryostatin 1 (BRYO; NSC 339555)” NCT00006022 ↗ |
| Action | Inhibit | “Consistent inhibition of PKC isoform eta (eta) in peripheral blood mononuclear cells was observed following bryo.” PMID 19221754 ↗ Feb 2009 |
| Modality | Small molecule | “Bryostatin 1 is a macrocyclic lactone” PMID 17145828 ↗ Dec 2006 |
| Route | Intravenous | “bryostatin 1 IV over 24 hours on day 1” NCT00003132 ↗ |